SIR 2024
Interventional Oncology
David Chlorogiannis, MD
Research Scholar
Brigham and Women's Hospital, Harvard Medical School
Financial relationships: Full list of relationships is listed on the CME information page.
Anargyros Chlorogiannis, BS
Department of Health Economics
Karolisnka Institutet, Sweden
Disclosure information not submitted.
Dimitrios Filippiadis, MD, PhD, MS (he/him/his)
Associate Professor in Interventional Radiology
University General Hospital "ATTIKON", Greece
Financial relationships: Full list of relationships is listed on the CME information page.
Alexis Kelekis, MD, PhD, FSIR (he/him/his)
Professor of Diagnostic and Interventional Radiology
University Of Athens, Greece
Disclosure information not submitted.
Gregory Makris
Disclosure information not submitted.
Marisabel Linares Bolsegui, MD
Research Scholar
Johns Hopkins Hospital
Disclosure information not submitted.
Christos Georgiades, MD, PhD
Professor, Director of Interventional Oncology
Johns Hopkins University
Disclosure information not submitted.
MEDLINE, EMBASE, and the CENTRAL databases were systematically searched, according to the PRISMA Guidelines, from inception to May 1, 2023. Cohort studies that included eGFR (eGFR) decline and SCr decline were included. Meta-analysis was performed by measuring the weighted mean difference and by fitting random-effect models.
Results: Overall, 37 studies were included, comprising of 2,943 participants with a median follow-up of 12 months (Inter Quantile Range (IQR): 3,75-29.75). PCA was associated with an absolute eGFR reduction of -3.04 ml/min/1.73 m2 (95% CI: −4.14 to −1.95; p-value < 0.001) and SCr increase of 0.05 mg/dl (95% CI: -0.02 to 0.11; p-value > 0.05). The weighted absolute mean difference of percutaneous cryoablation for treating stage T1b renal cell carcinoma was estimated at -5.19 ml/min/1.73 m2 (95% CI: −11.1 to 0.72; p-value > 0.05).
Conclusion: Percutaneous cryoablation for stage 1 renal cell carcinoma does not cause any clinically significant changes in eGFR or SCr. Same conclusion was supported for larger tumors (T1b).